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ACTIVE COMBINATION IMMUNOCHEMOTHERAPY WITH 
INTERFERON-民 INTERLEUKIN-2AND GEMCIT ABINE 
FOR FOUR PATIENTS WITH METASTATIC 
RENAL CELL CARCINOMA 
Takamitsu INOUE， Chikara OHYAMA， Shingo HATAKEYAMA， Yohei HORlKAWA， 
Hisafumi TOGASHI， Norihiko TSUCHIYA， Shinobu MATSUURA， Shigeru SATOH， 
Kazunari SATO and Tomonori HABUCHI 
The Department o} Urology， Akita Univeη砂 Schoolo} Medicine 
Immunochemotherapy consisting of interferon-α(IFN-α)， interleukin-2 (IL-2)， and gemcitabine 
(GEM) for metastatic renal cell carcinoma. 
A partial response maintained for 15 months， was obtained in one case resistant to IFN-αand IL-2 
of para-aortic lymph node metastases (case 1). A minor response with 30% reduction of lung 
metastasis was obtained in one IFN-αresistant case， and the duration was 6 months (case 2). In one 
case， incontra-lateral renal metastasis， no disease progression was obtained for 6 months (case 3). 
One case with resistance to IFN-αand IL-2， and who had preoperative abnormalities of corrected 
serum calcium， serum c-reactive protein and hemoglobin， had progressive disease and died of cancer 
after 6 months (case 4). Grade 3 toxicity was noted in leucopenia (4/4)， anemia (1/4)， and nausea/ 
vomiting (1/4). 
Although the response duration was short， the combination immunochemotherapy consisting of 
IFN司久 IL-2and GEM may be a promising salvage regimen for the patients with metastatic renal cell 
carcmoma. 
(Hinyokika Kiyo 51: 165-169， 2005) 




























を2カ月間投与したが不変 (nochange : NC)であっ
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Fig. 1. Abdominal CT of case 1 before (Fig. 
la) and after (Fig. lb) 3 courses of the 
immunochemotherapy. Marked reduc-
tion of lymph node metastases was 
observed (arrow heads). 
Table 1. Regimen of combination therapy 
consisting of interferon-alpha， inter-
leukin-2， and gemcitabine 
Therapeutics Dose Day (28 day-cycle) 
Interferon-alpha 3.0X 106 IU 2 times/week 
Interleukin-2 7.0-21.0X 10; IU 2 times/week 
Gemcitabine 1，0∞mg/m2 Days 1，8， 15
た (Fig.1 a). 2002年12月より IFNα，IL-2， GEM 
併用療法 (Table1)を3コース施行し，縮小率99%
以上と有効 (partialrcsponse: PR) をえた (Fig.







(RCC， clear cel carcinoma， G3， pT3bNOM 1). 
2003年3月から肺転移に対し IFNα 療法 (300万単位
X3回/週) を3カ月間施行したが転移巣の;増大を認
めた (Fig.2a). 2003年6月より IFNα，IL・2，GEM 
Fig. 2. Chest CT of case 2 before (Fig. 2a) 




よび grade3の白血球減少， grade 2の血清 AST，
ALTの上昇および grade1の咳を認めた.その後，










IFNα， IL-2， GEM併用療法 (Tablc1)を開始した


















































RCC， clear cel carcinoma， 
GI-2， pT2NOMO 
RCC c¥ear cel carcinoma， 
G3， pT3bNOMI 
RCC c¥ear cel carcinoma， 
GI， pT3apNOMO 
RCC mixed cel carcinoma， 
G2， pT3bNOMO， v (+) 
rt. nephrectomy 
It. nephrectomy 
rt. renal tumor， 
¥Ocm 
It. renal tumor， 
9cm 
rt. renal tumor， 
6cm 















IFNa rt. N ephrectomy M 51 3 
O PD 2 IFNa+IL・2Lung (multiple) rt. N ephrectomy， thrombectomy F 52 4 
??????
Table 3. Risk factors of the patients 
Serum c-reactive 







Serum alkaline pho.s~ 
phatase (105-359U/I) 
Serum lactate dehvdro-
genase (124-234 U/I) 
Hemol!"lobin 
j♂13凶 2g/dlj
♀ 12.0-15.2 g/dl 
Karnofsky perform-
ance status (%) 
0.0 4.8 9.4 8.6 77 183 13.8 90 
1.2 3.8 9.1 9.3 214 195 11.7 80 
???????
?? ?
4.5 9.0 8.5 176 194 13.6 90 
???
4.3 9.0 8.7 218 162 12.4 80 
0.1 5.2 8.5 7.3 141 146 15.1 100 
0.1 4.1 8.6 8.7 189 148 13.6 
? ????


















0.1 4.5 9.4 8.9 223 198 10.7 70 
?
???
* corrected serum calcium=serum calcium+(4-serum albumin)，料 immunochemotherapyconsisting of interferon-a， interleukin-2， and gemc出 bine.
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Table 4. Combination therapy for metastasis of renal cell carcinoma using gemcitabine 
Regimen (reference) N CR+PR (%) NC (%) Grade 3-4 to置icity
GEM (4) 37 3 ( 8) 18 (48) Neutropenia (5%)， nausea/vomitti時 (21%)
GEM + IFNa (6) 9 0 ( 0) 8 (89) 
GEM+5・FU(7) 39 7 (17) 
GEM + IFNa+ IL-2 (5) 14 








施行 (RCCclear cel carcinoma， G2， pT3bNOMO). 
術前の末梢血ヘモグロビン濃度 (Hb)は9.7g/dl (基
準値 12.0-15.2g/dJ)， c-reactive protein (CRP)は
6.9mg/dl (基準値 0-0.3mg/dJ) ， albuminは 3.5




した. IFNα(600万単位X2回/週)， IL-2 (140万単
位 X2回/週)併用療法を施行したが PDであり，
2003年6月から IFNα， IL-2， GEM併用療法
(Table 1) を開始した.開始時の Karnofskyper幽
formance status (KPS)は70%であった. 2コース後
の評価で転移巣の増大を認め (PD)，さらに副作用
(発熱)も強く，中止した，副作用は grade2の発





(%)， Hb，血清 lactatedehydrogenase (LDH) ，血
清 alkalinephosphatase (ALP) ，血清 Ca，補正血清
















Neutropenia (14%)， fatigue (7%)， mucositis (10%)， ane-
mia (5%) 
Neutropenia (7%)， flu-like symptoms 
Neutropenia (28%)， anorexia (13%)， mucositis (18%)， fa-
tigue (~8 %)， eever(8 %)， nausea (8 %) 















腎細胞癌への GEM単独療法については phase1 


































副作用は grade1の発熱を 2例に， grade 3の悪心
胆吐を l例で認め，末梢血では grade3の白血球減
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